Effects of epanolol and metoprolol on the heart measured by 24-hour holter monitoring
- PMID: 2575985
- DOI: 10.2165/00003495-198900382-00017
Effects of epanolol and metoprolol on the heart measured by 24-hour holter monitoring
Abstract
Continuous 24-hour ECG monitoring was performed as an additional objective in 87 patients from 5 centres in the VISA 1 study. The aim of the study was to compare the continuous 24-hour ECG recordings before the study and during treatment with epanolol ('Visacor') or metoprolol. Parameters of particular interest were heart rate and premature ventricular contractions (PVCs). Using the Oxford 4000 system with a 5-lead recorder, 24-hour monitoring was carried out on entry to the study (no antianginal therapy was allowed, with the exception of short acting nitrates), and at the end of both treatment periods. Measurements included the total number of heart beats and PVCs and the incidence of bradycardia. 87 patients, of mean age 59 (range 32 to 80) years, were included in the study. 62 patients had evaluable tapes available on both active treatment periods. The mean heart rate during 24 hours was significantly lower with metoprolol compared with epanolol treatment (64 vs 72 beats/min, respectively, p less than 0.001). The total number of PVCs in 24 hours was similar in both treatment groups and not significantly different from the value recorded at entry. The median total duration of bradycardia (heart rate less than 60 beats/min) in 24 hours was significantly (p less than 0.001) less for epanolol (60 minutes) than metoprolol (428 minutes). Plots of the mean hourly heart rates show that during daytime, epanolol was associated with a mean heart rate in between the rate observed without treatment and with metoprolol treatment. At night-time, almost identical values were found in the groups treated with epanolol compared with the non-treatment period, whereas the metoprolol treatment induced significant lower heart rate levels. Thus, it was shown that there was greater heart rate reduction with metoprolol than with epanolol (p less than 0.001), and that there was no heart rate reduction at night with epanolol. No arrhythmogenic effect was seen for either drug.
Similar articles
-
Efficacy of epanolol versus metoprolol in angina pectoris: report from a Swedish multicentre study of exercise tolerance.J Intern Med. 1992 Jan;231(1):7-11. doi: 10.1111/j.1365-2796.1992.tb00491.x. J Intern Med. 1992. PMID: 1346268 Clinical Trial.
-
Comparative multicentre study of the tolerability and efficacy of epanolol versus metoprolol in patients with stable angina pectoris.Drugs. 1989;38 Suppl 2:55-60. doi: 10.2165/00003495-198900382-00014. Drugs. 1989. PMID: 2575982 Clinical Trial.
-
Left ventricular function during treatment with either metoprolol or epanolol.Drugs. 1989;38 Suppl 2:70. doi: 10.2165/00003495-198900382-00018. Drugs. 1989. PMID: 2575986 No abstract available.
-
An overview of clinical trial experience with epanolol.Drugs. 1989;38 Suppl 2:81-5. doi: 10.2165/00003495-198900382-00022. Drugs. 1989. PMID: 2575988 Review.
-
Clinical pharmacology of epanolol. Pharmacodynamic aspects.Drugs. 1989;38 Suppl 2:18-27. doi: 10.2165/00003495-198900382-00006. Drugs. 1989. PMID: 2575976 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous